HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The adoption of nintedanib in systemic sclerosis: the SENSCIS study.

Abstract
Nintedanib shows a statistically significant effect on lung function decay in patients with ILD secondary to systemic sclerosis, but no effect on skin fibrosis and on health-related quality of life http://bit.ly/2vfJRj7.
AuthorsTeresa Bruni, Francesco Varone
JournalBreathe (Sheffield, England) (Breathe (Sheff)) Vol. 16 Issue 2 Pg. 200005 (Jun 2020) ISSN: 1810-6838 [Print] England
PMID32665787 (Publication Type: Journal Article)
CopyrightCopyright ©ERS 2020.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: